Paclitaxel

About

Therapy type: Chemotherapy

Therapy strategy: Taxane-based chemotherapy

Mappings

NCI Thesaurus: Paclitaxel (ncit:C1411)

RxNorm: paclitaxel (rxcui:56946, omop:4306859)

SNOMED: Paclitaxel (sctid:387374002, omop:1378382)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Paclitaxel
EMA (1) FDA (1)	dMMR	Endometrial Carcinoma	Carboplatin, Dostarlimab, Paclitaxel
EMA (1) FDA (1)	MSI-H	Endometrial Carcinoma	Carboplatin, Dostarlimab, Paclitaxel
EMA (1) FDA (1)	dMMR	Endometrial Carcinoma	Carboplatin, Durvalumab, Paclitaxel
EMA (2) FDA (2) HSE (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel
FDA (1)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Cisplatin, Paclitaxel, Pembrolizumab
FDA (1)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Pembrolizumab
FDA (1)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab
FDA (1)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab
EMA (1) FDA (1) HSE (1)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Carboplatin, Paclitaxel, Pembrolizumab
FDA (1)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Carboplatin, Paclitaxel, Pembrolizumab
EMA (1) FDA (1) HSE (1)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
FDA (1)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
FDA (1) HSE (4)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab
EMA (1) FDA (1)	ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative	Invasive Breast Carcinoma	Paclitaxel, Pembrolizumab
EMA (2) FDA (4) HSE (1)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab
EMA (1) FDA (2)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
EMA (2) FDA (2) HSE (1)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
EMA (2) FDA (2) HSE (1)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab
EMA (1) FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Paclitaxel
EMA (2) HSE (2)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab
EMA (1) HSE (1)	HER2-positive	Invasive Breast Carcinoma	Doxorubicin, Paclitaxel, Trastuzumab
EMA (2)	ERBB2 amplification	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab
EMA (1)	ERBB2 amplification	Invasive Breast Carcinoma	Doxorubicin, Paclitaxel, Trastuzumab
EMA (1)	pMMR	Endometrial Carcinoma	Carboplatin, Durvalumab, Olaparib, Paclitaxel
EMA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Paclitaxel, Pembrolizumab
EMA (2) HSE (2)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel
EMA (1)	EGFR somatic variants	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
EMA (1)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
HSE (2)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab
HSE (2)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Pertuzumab, Trastuzumab
HSE (2)	HER2-negative	Invasive Breast Carcinoma	Bevacizumab, Paclitaxel
EMA (1)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab
EMA (1)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Oxaliplatin, Paclitaxel, Tislelizumab
FDA (1)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab
FDA (1)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Oxaliplatin, Paclitaxel, Tislelizumab
FDA (1)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab
FDA (1)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Oxaliplatin, Paclitaxel, Tislelizumab
FDA (1)	PD-L1 (CPS) >= 1	Ovarian Epithelial Tumor	Paclitaxel, Pembrolizumab
FDA (1)	PD-L1 (CPS) >= 1	Ovarian Epithelial Tumor	Bevacizumab, Paclitaxel, Pembrolizumab
FDA (1)	PD-L1 (CPS) >= 1	High-Grade Serous Fallopian Tube Cancer	Paclitaxel, Pembrolizumab
FDA (1)	PD-L1 (CPS) >= 1	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Paclitaxel, Pembrolizumab
FDA (1)	PD-L1 (CPS) >= 1	Peritoneal Serous Carcinoma	Paclitaxel, Pembrolizumab
FDA (1)	PD-L1 (CPS) >= 1	Peritoneal Serous Carcinoma	Bevacizumab, Paclitaxel, Pembrolizumab